Key Points
- Director Bruce Booth sold 81,866 shares on March 2 at an average price of $90.13 for roughly $7.38M, reducing his stake by 10.81% to 675,341 shares (disclosed in an SEC Form 4).
- Kymera missed recent quarterly estimates, reporting EPS of ($0.97) vs. ($0.77) expected and revenue of $2.87M vs. $14.8M expected, with revenue down 60.8% year‑over‑year and a deeply negative net margin.
- Analysts remain broadly bullish, with several firms raising price targets (UBS to $128, HC Wainwright to $134) and an average target of $119.50, while the company is viewed as well‑funded (~$1.6B cash) and has upcoming clinical catalysts (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027).
Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) COO Jeremy Chadwick sold 2,039 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $88.93, for a total value of $181,328.27. Following the transaction, the chief operating officer owned 77,729 shares in the company, valued at approximately $6,912,439.97. This represents a 2.56% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Kymera Therapeutics Trading Down 3.5%
NASDAQ KYMR traded down $3.05 on Thursday, hitting $83.06. The company's stock had a trading volume of 84,067 shares, compared to its average volume of 791,857. The firm has a market cap of $6.78 billion, a P/E ratio of -22.57 and a beta of 2.20. Kymera Therapeutics, Inc. has a 52-week low of $19.44 and a 52-week high of $103.00. The company's 50-day simple moving average is $78.75 and its 200 day simple moving average is $66.40.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million for the quarter, compared to analysts' expectations of $14.80 million. During the same period last year, the firm posted ($0.88) earnings per share. Kymera Therapeutics's quarterly revenue was down 60.8% on a year-over-year basis. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.
Key Headlines Impacting Kymera Therapeutics
Here are the key news stories impacting Kymera Therapeutics this week:
- Positive Sentiment: Major price‑target upgrades and bullish analyst notes are supporting buying interest — UBS raised its target sharply (to $128) and reiterated a Buy view, highlighting pipeline progress as a catalyst. Read More.
- Positive Sentiment: HC Wainwright trimmed near‑term loss forecasts (small EPS improvements across Q1–Q4 2026) while keeping a Buy rating and a $134 target, signaling better-than-expected operational assumptions and sustaining constructive analyst sentiment. Read More.
- Positive Sentiment: Coverage and commentary emphasize a strong cash runway (~$1.6B) and upcoming program milestones (KT‑579 data in 2H26; KT‑621 Phase 2b readouts in 2027) that are material longer‑term catalysts. That combination supports risk‑on positioning for clinical‑stage biotechs. Read More.
- Neutral Sentiment: Technical/contextual factors: KYMR is trading above its 200‑day moving average with elevated volatility (beta ~2.2); analysts’ average target remains well above current levels, which can amplify momentum but also heighten swings. Read More.
- Negative Sentiment: Large director sale — Director Bruce Booth sold 81,866 shares (~$7.38M at ~$90). A sale of that size by a director can be perceived as significant profit‑taking and may cap short‑term upside or increase volatility. Read More.
- Negative Sentiment: Multiple senior executives (CFO, COO and another insider) disclosed sales across March 2–4 at ~$85–$89, each trimming positions by a few percent. Repeated insider selling can raise governance or sentiment concerns even if it’s routine liquidity management. Read More.
Analyst Upgrades and Downgrades
A number of equities analysts recently issued reports on KYMR shares. Barclays increased their price target on shares of Kymera Therapeutics to $133.00 and gave the stock an "overweight" rating in a research note on Tuesday, January 27th. Weiss Ratings reissued a "sell (d-)" rating on shares of Kymera Therapeutics in a research report on Thursday, January 22nd. Oppenheimer raised their target price on Kymera Therapeutics from $67.00 to $120.00 and gave the company an "outperform" rating in a research note on Tuesday, December 9th. UBS Group upped their price target on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, Mizuho raised their price objective on Kymera Therapeutics from $81.00 to $120.00 and gave the company an "outperform" rating in a research report on Thursday, December 11th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $119.50.
Get Our Latest Report on Kymera Therapeutics
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in KYMR. Smartleaf Asset Management LLC boosted its holdings in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company's stock worth $42,000 after acquiring an additional 424 shares in the last quarter. Larson Financial Group LLC raised its position in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company's stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the 4th quarter worth about $63,000. PNC Financial Services Group Inc. grew its position in Kymera Therapeutics by 506.6% during the 2nd quarter. PNC Financial Services Group Inc. now owns 922 shares of the company's stock valued at $40,000 after purchasing an additional 770 shares during the last quarter. Finally, Bessemer Group Inc. increased its stake in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company's stock valued at $53,000 after purchasing an additional 815 shares in the last quarter.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.
The company's pipeline emphasizes immunology and oncology.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
